In Phase III MINT trial, Uplizna (inebilizumab) demonstrated significant short-term efficacy and a manageable safety profile ...

Insomnia is a significant health and quality of life concern for older adults, with up to half of all adults over the age of 65 experiencing insomnia symptoms.

Tolebrutinib slows disability progression in adults with nonrelapsing secondary progressive multiple sclerosis (MS).

BNP Paribas Exane initiated coverage of Sanofi (SNY) with an Outperform rating and $65 price target Stay Ahead of the Market: Discover ...

Tolebrutinib, a brain-penetrant BTK inhibitor, may fill a significant unmet need by delaying disability progression in patients with non-relapsing secondary progressive multiple sclerosis.

Analysts fell to the sidelines weighing in on Sanofi (SNYNF – Research Report) and HealthStream (HSTM – Research Report) with neutral ratings, ...

Two researchers win the Breakthrough Prize in Life Sciences for their discoveries related to multiple sclerosis disease ...

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive ...

Tolebrutinib, a novel BTK inhibitor that targets neuroinflammation, slowed disability progression by 31% in nrSPMS, a phase 3 ...